METHODS: Totally 33 patients(58 eyes)with DME were divided into two groups. Group A(laser group)received STMP yellow laser, and group B(combined treatment group)received ranibizumab intravitreal injection combined with STMP yellow laser. The best corrected visual acuity(BCVA), intraocular pressure(IOP), central macular thickness(CMT), total macular volume(TMV), fluorescein fundus angiography(FFA), multifocal ERG(MERG), autofluorescence(AF)and macular pigment optical density(MPOD)were compared before and after the treatments. And treatment times were counted.

RESULTS:Compared with those before treatment, there were significant differences in BCVA and TMV 6, 9, 12mo after treatment in the laser group(P<0.05). And there were significant differences in BCVA and TMV 3, 6, 9, 12mo after treatment in the combined treatment group(P<0.05). For both groups, there were significant differences in CMT before and 3, 6, 9, 12mo after treatment(P<0.01). Compared with the P1 amplitude of MEG, Max OD and Mean OD before treatment, there were significant differences for the two groups 12mo after treatment(P<0.01). And the differences were significant in TMV and P1 amplitudes between the two groups after 12mo of treatment(P<0.01). During the follow-up period, the laser times was 3.32±1.09 in the laser group and 3.30±1.18 in the combined treatment group(P=0.943).

CONCLUSION:Both single STMP laser and combined with intravitreal injection of ranibizumab can effectively reduce macular edema, improve vision and safety in DME patients. And the combined treatment group has faster and better effect.